AIM: To assess effects of allicor (a long-acting garlic drug) on the risk of ischemic heart disease (IHD) in primary prophylaxis of cardiovascular diseases. MATERIAL AND METHODS: A double blind placebo-controlled study investigated for a year changes in multifactorial risks of cardiovascular events or their complications in 167 patients with hyperlipidemia free of IHD. RESULTS: In men, intake of allicor for 12 months resulted in a 10.7% reduction of a 10-year absolute risk to develop IHD (p < 0.05) and decreased a 10-year absolute risk of acute myocardial infarction and sudden death by 22.7% (p < 0.05). In women, allicor prevented age-related cardiovascular risk (p < 0.05). Among lipid parameters, the greatest fall was observed for total cholesterol and LDLP cholesterol (p < 0.05) in men by 27.9 and 22.5 mg/dl, in women--by 11.4 and 10.8 mg/dl, respectively. CONCLUSION: Allicor is effective in reducing multifactorial risk of cardiovascular diseases.
RCT Entities:
AIM: To assess effects of allicor (a long-acting garlic drug) on the risk of ischemic heart disease (IHD) in primary prophylaxis of cardiovascular diseases. MATERIAL AND METHODS: A double blind placebo-controlled study investigated for a year changes in multifactorial risks of cardiovascular events or their complications in 167 patients with hyperlipidemia free of IHD. RESULTS: In men, intake of allicor for 12 months resulted in a 10.7% reduction of a 10-year absolute risk to develop IHD (p < 0.05) and decreased a 10-year absolute risk of acute myocardial infarction and sudden death by 22.7% (p < 0.05). In women, allicor prevented age-related cardiovascular risk (p < 0.05). Among lipid parameters, the greatest fall was observed for total cholesterol and LDLP cholesterol (p < 0.05) in men by 27.9 and 22.5 mg/dl, in women--by 11.4 and 10.8 mg/dl, respectively. CONCLUSION: Allicor is effective in reducing multifactorial risk of cardiovascular diseases.